Transfusion-transmitted cytomegalovirus infection.
Transfusion-associated cytomegalovirus (CMV) infections is associated with significant morbidity and mortality in immunocompromised seronegative patients. Seronegative blood products reduce the incidence of infection to less than 7%. Filtered blood may be an effective alternative to seronegative blood products for prevention of transfusion-associated CMV infection. The clinical significance of second strain CMV infection remains undefined.
Bowden
R A
RA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
D000328:Adult; D003587:Cytomegalovirus / Q000276:immunology / Q000302:isolation & purification; D003586:Cytomegalovirus Infections / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control / Q000635:transmission*; D005544:Forecasting; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D007231:Infant, Newborn; D017708:Leukocyte Transfusion / Q000009:adverse effects; D007962:Leukocytes / Q000821:virology; D008403:Mass Screening; D015995:Prevalence; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D065227:Transfusion Reaction; D014180:Transplantation / Q000009:adverse effects; D014766:Viremia / Q000821:virology